222 related articles for article (PubMed ID: 26895472)
21. The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials.
Fang Y; Qu X; Cheng B; Chen Y; Wang Z; Chen F; Xiong B
Tumour Biol; 2015 Mar; 36(3):1933-41. PubMed ID: 25387808
[TBL] [Abstract][Full Text] [Related]
22. A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO).
Decker T; Overkamp F; Rösel S; Nusch A; Göhler T; Indorf M; Sahlmann J; Trarbach T
BMC Cancer; 2017 Jul; 17(1):499. PubMed ID: 28743247
[TBL] [Abstract][Full Text] [Related]
23. [Exemestane-everolimus in HER2-negative, hormonal receptor-positive, post-menopausal metastatic breast cancer with resistance to non-steroidal aromatase inhibitor: a new option].
Gilabert M; Launay S; Gonçalves A
Bull Cancer; 2014 Mar; 101(3):325-33. PubMed ID: 24691195
[TBL] [Abstract][Full Text] [Related]
24. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.
Valachis A; Polyzos NP; Patsopoulos NA; Georgoulias V; Mavroudis D; Mauri D
Breast Cancer Res Treat; 2010 Jul; 122(1):1-7. PubMed ID: 20063120
[TBL] [Abstract][Full Text] [Related]
25. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
26. Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis.
Raphael J; Desautels D; Pritchard KI; Petkova E; Shah PS
Eur J Cancer; 2018 Mar; 91():38-46. PubMed ID: 29331750
[TBL] [Abstract][Full Text] [Related]
27. Everolimus in hormone receptor-positive advanced breast cancer: targeting receptor-based mechanisms of resistance.
Shtivelband MI
Breast; 2013 Aug; 22(4):405-10. PubMed ID: 23499266
[TBL] [Abstract][Full Text] [Related]
28. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
Zardavas D; Fumagalli D; Loi S
Curr Opin Oncol; 2012 Nov; 24(6):623-34. PubMed ID: 22960556
[TBL] [Abstract][Full Text] [Related]
29. The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part II: Metastatic Disease.
Hill A; Gutierrez E; Liu J; Sammons S; Kimmick G; Sedrak MS
Drugs Aging; 2020 May; 37(5):349-358. PubMed ID: 32227289
[TBL] [Abstract][Full Text] [Related]
30. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.
Prat A; Baselga J
Nat Clin Pract Oncol; 2008 Sep; 5(9):531-42. PubMed ID: 18607391
[TBL] [Abstract][Full Text] [Related]
31. Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials.
Omarini C; Piacentini F; Sperduti I; Barbolini M; Isca C; Toss A; Cortesi L; Barbieri E; Dominici M; Moscetti L
BMC Cancer; 2020 May; 20(1):418. PubMed ID: 32404154
[TBL] [Abstract][Full Text] [Related]
32. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
33. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Jerusalem G; Bachelot T; Barrios C; Neven P; Di Leo A; Janni W; de Boer R
Cancer Treat Rev; 2015 Feb; 41(2):94-104. PubMed ID: 25575443
[TBL] [Abstract][Full Text] [Related]
34. Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer.
Maurer C; Ferreira AR; Martel S; Lambertini M; Pondé N; Aftimos P; de Azambuja E; Piccart M
Breast; 2018 Jun; 39():14-18. PubMed ID: 29474991
[TBL] [Abstract][Full Text] [Related]
35. Effect of pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer: A meta-analysis
.
Tian T; Ye J; Zhou S
Int J Clin Pharmacol Ther; 2017 Sep; 55(9):720-727. PubMed ID: 28737130
[TBL] [Abstract][Full Text] [Related]
36. Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer.
Ciruelos E; Cortes-Funes H; Ghanem I; Manso L; Arteaga C
Anticancer Drugs; 2013 Sep; 24(8):769-80. PubMed ID: 23838677
[TBL] [Abstract][Full Text] [Related]
37. A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer.
Generali D; Venturini S; Rognoni C; Ciani O; Pusztai L; Loi S; Jerusalem G; Bottini A; Tarricone R
Breast Cancer Res Treat; 2015 Jul; 152(1):95-117. PubMed ID: 26044370
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of PI3K/AKT/mTOR pathway inhibitors for the treatment of advanced solid cancers: A literature-based meta-analysis of 46 randomised control trials.
Li X; Dai D; Chen B; Tang H; Xie X; Wei W
PLoS One; 2018; 13(2):e0192464. PubMed ID: 29408858
[TBL] [Abstract][Full Text] [Related]
39. Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy.
Niraula S; Ocana A
Cancer Treat Rev; 2016 Nov; 50():168-174. PubMed ID: 27693931
[TBL] [Abstract][Full Text] [Related]
40. HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.
Bartlett JMS; Ahmed I; Regan MM; Sestak I; Mallon EA; Dell'Orto P; Thürlimann B; Seynaeve C; Putter H; Van de Velde CJH; Brookes CL; Forbes JF; Viale G; Cuzick J; Dowsett M; Rea DW;
Eur J Cancer; 2017 Jul; 79():129-138. PubMed ID: 28494403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
